BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ONC BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

Market Closed 04-02 16:00:00 EDT

310.79

+2.35

+0.76%

盘后313.00

+2.21+0.71%

19:55 EDT

High315.97	Low306.33	Vol133.52K
Open307.42	D1 Closing308.44	Amplitude3.13%
Mkt Cap36.85B	Tradable Cap23.53B	Total Shares118.57M
T/O41.57M	T/O Rate0.18%	Tradable Shares75.70M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","latestPrice":310.79,"timestamp":1775160000000,"preClose":308.44,"halted":0,"volume":133520,"hourTrading":{"tag":"盘后","latestPrice":313,"preClose":310.79,"latestTime":"19:55 EDT","volume":3229,"amount":1005658.79,"timestamp":1775174136445,"change":2.21,"changeRate":0.007111,"amplitude":0.007111},"delay":0,"changeRate":0.007618985864349704,"floatShares":75698900,"shares":118570700,"eps":2.469999,"marketStatus":"Market Closed","change":2.35,"latestTime":"04-02 16:00:00 EDT","open":307.42,"high":315.97,"low":306.325,"amount":41574130.4112,"amplitude":0.03127,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.469999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775462400000},"marketStatusCode":7,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":308.44,"preHourTrading":{"tag":"盘前","latestPrice":308.44,"preClose":308.44,"latestTime":"09:09 EDT","volume":448,"amount":137520.3648,"timestamp":1775135354845,"change":0,"changeRate":0,"amplitude":0.007392},"postHourTrading":{"tag":"盘后","latestPrice":313,"preClose":310.79,"latestTime":"19:55 EDT","volume":3229,"amount":1005658.79,"timestamp":1775174136445,"change":2.21,"changeRate":0.007111,"amplitude":0.007111},"volumeRatio":0.5559449465599962,"impliedVol":0.4959,"impliedVolPercentile":0.761},"requestUrl":"/m/hq/s/ONC","defaultTab":"news","newsList":[{"id":"2622090085","title":"Is BeOne Medicines (ONC) Pricing In Too Much Optimism After Recent Share Price Drop?","url":"https://stock-news.laohu8.com/highlight/detail?id=2622090085","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622090085?lang=en_us&edition=fundamental","pubTime":"2026-03-25 01:13","pubTimestamp":1774372427,"startTime":"0","endTime":"0","summary":"If you are wondering whether BeOne Medicines at US$274.73 is still a fair deal or already pricing in a lot of optimism, the valuation picture is the place to start.\nThe stock has been volatile recently, with a 5.2% decline over the last week and a 24.1% decline over the last 30 days. Over longer periods, the 1 year return sits at 8.5% and the 3 year return at 22.2%, while the 5 year return is a 15.1% decline.\nRecent news coverage has focused on BeOne Medicines as part of the broader...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/is-beone-medicines-onc-pricing-in-too-much-optimism-after-re","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/is-beone-medicines-onc-pricing-in-too-much-optimism-after-re","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","MDCO","ONC","DCF","BK4588","BK4526","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620238566","title":"Barclays Sticks to Its Buy Rating for BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620238566","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620238566?lang=en_us&edition=fundamental","pubTime":"2026-03-18 15:35","pubTimestamp":1773819346,"startTime":"0","endTime":"0","summary":"Barclays analyst Etzer Darout maintained a Buy rating on BeOne Medicines today and set a price target of $405.00. Darout covers the Healthcare sect...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-its-buy-rating-for-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-its-buy-rating-for-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONC","MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620608764","title":"Early Cancer Drug Trial Termination Highlights Pipeline Risk for BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620608764","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620608764?lang=en_us&edition=fundamental","pubTime":"2026-03-17 00:30","pubTimestamp":1773678655,"startTime":"0","endTime":"0","summary":"BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines has reported a key update on a BeiGene-sponsored early ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/early-cancer-drug-trial-termination-highlights-pipeline-risk-for-beone-medicines-onc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/early-cancer-drug-trial-termination-highlights-pipeline-risk-for-beone-medicines-onc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","MDCO","BK4526","BK4588","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619465147","title":"BeOne Medicines Cut to Hold From Buy by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2619465147","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619465147?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:09","pubTimestamp":1773666540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ONC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 09:09 ET (13:09 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","BK4139","BK4588","BK4585","ONC","MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619009120","title":"Is It Time To Reassess BeOne Medicines (ONC) After Recent Share Price Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2619009120","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619009120?lang=en_us&edition=fundamental","pubTime":"2026-03-15 02:30","pubTimestamp":1773513002,"startTime":"0","endTime":"0","summary":"If you are wondering whether BeOne Medicines at around US$284.05 is giving you fair value or a potential mispricing, this article will walk through what the current market price might be saying about the business.\nThe stock has seen mixed returns, with a 5.7% decline over the last 7 days and a 19.1% decline over the last 30 days, set against a 27.2% return over 3 years and 9.6% over 1 year. These figures can change how investors view both its growth prospects and risk.\nRecent coverage of...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/is-it-time-to-reassess-beone-medicines-onc-after-recent-shar","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/is-it-time-to-reassess-beone-medicines-onc-after-recent-shar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MDCO","DCF","BK4588","BK4139","ONC","BK4585","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149692976","title":"BEIGENE Allots 741,300 Shares Under Equity Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1149692976","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149692976?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:48","pubTimestamp":1773272890,"startTime":"0","endTime":"0","summary":"BEIGENE (06160) announced the issuance of 741,300 shares on March 11, 2026, in accordance with its equity incentive plan.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","BK1588","BK4139","LU0588546209.SGD","LU2328871848.SGD","LU0307460666.USD","BK4526","LU1770034418.SGD","LU1251922891.USD","BK1161","LU1719994722.HKD","LU1969619763.USD","BK1500","BK1583","BK0239","LU1303224171.USD","688235","BK4588","BK4585","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133043967","title":"BEIGENE Announces New Enrollment Period for 2018 Employee Stock Purchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1133043967","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133043967?lang=en_us&edition=fundamental","pubTime":"2026-03-10 16:56","pubTimestamp":1773132982,"startTime":"0","endTime":"0","summary":"BEIGENE (06160) has announced that the new enrollment period for its 2018 Employee Stock Purchase Plan will run from March 2, 2026, to August 31, 2026. Eligible employees will purchase shares,...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","LU1969619763.USD","LU0588546209.SGD","LU2328871848.SGD","ONC","BK1500","LU1719994722.HKD","BK1583","LU1251922891.USD","BK1588","BK1161","06160","LU1303224171.USD","LU0307460666.USD","BK4585","BK0239","BK4526","688235","LU1770034418.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147967863","title":"BeiGene Grants Restricted Stock Units Equivalent to 21,200 ADSs","url":"https://stock-news.laohu8.com/highlight/detail?id=1147967863","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147967863?lang=en_us&edition=fundamental","pubTime":"2026-03-08 10:42","pubTimestamp":1772937727,"startTime":"0","endTime":"0","summary":"BeiGene (06160) announced that on March 2, 2026, the Board Compensation Committee granted a total of 21,200 restricted stock units representing American Depositary Shares to 180 recipients under the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0588546209.SGD","688235","LU1770034418.SGD","BK1583","BK4139","LU0307460666.USD","BK4526","06160","BK4585","LU1969619763.USD","LU1251922891.USD","LU1719994722.HKD","BK1500","LU2328871848.SGD","BK1588","ONC","BK0239","BK1161","BK4588","LU1303224171.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143093153","title":"BEIGENE Grants 21,200 Restricted Stock Units in the Form of ADSs","url":"https://stock-news.laohu8.com/highlight/detail?id=1143093153","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143093153?lang=en_us&edition=fundamental","pubTime":"2026-03-06 17:23","pubTimestamp":1772788994,"startTime":"0","endTime":"0","summary":"BEIGENE (06160) announced that on March 2, 2026, the Board's Compensation Committee granted a total of 21,200 restricted stock units in the form of American Depositary Shares to 180 grantees under...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1500","LU1303224171.USD","BK4526","688235","LU1251922891.USD","LU0588546209.SGD","BK1588","ONC","BK0239","LU1770034418.SGD","BK4588","BK4139","BK1161","LU2328871848.SGD","LU1719994722.HKD","LU1969619763.USD","BK1583","06160","BK4585","LU0307460666.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128030808","title":"First Batch of Companies Set to Exit STAR Market Growth Layer, Including Cambricon and Beigene","url":"https://stock-news.laohu8.com/highlight/detail?id=1128030808","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128030808?lang=en_us&edition=fundamental","pubTime":"2026-03-06 12:46","pubTimestamp":1772772412,"startTime":"0","endTime":"0","summary":"Several companies listed on the STAR Market's Growth Layer have recently released their preliminary financial results for 2025. Firms such as Cambricon Technologies Corporation Limited and Beigene...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGXZ49509284.SGD","BK4588","BK4139","LU1251922891.USD","LU2476274720.SGD","ONC","SG9999003461.SGD","LU0307460666.USD","LU2476274308.USD","SG9999001093.SGD","159982","LU1770034418.SGD","BK0239","LU1719994722.HKD","SG9999001051.SGD","SGXZ81163826.USD","06160","SG9999006597.SGD","BK0231","BK1588","BK1583","LU2778985437.USD","688256","SG9999001069.SGD","LU1969619763.USD","LU1303224171.USD","SGXZ90724238.SGD","BK1161","BK4526","BK4585","BK1500","SG9999002950.SGD","LU2328871848.SGD","LU0588546209.SGD","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617550807","title":"BeOne Medicines Pharma Alliances Contrast With High P/E And Valuation Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2617550807","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617550807?lang=en_us&edition=fundamental","pubTime":"2026-03-05 00:30","pubTimestamp":1772641827,"startTime":"0","endTime":"0","summary":"BeOne Medicines, listed as NasdaqGS:ONC, announced new collaborations with Amgen, Bristol Myers Squibb, and Novartis.\nThe partnerships are focused on advancing BeOne Medicines' oncology therapy pipeline alongside its existing commercial products.\nThe company also highlighted ongoing clinical trials that sit alongside these new pharma alliances.\n\nBeOne Medicines operates in oncology, an area where large pharma groups and smaller specialists often work together to bring new treatments through...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-pharma-alliances-contrast-with-high-pe-and-v","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-pharma-alliances-contrast-with-high-pe-and-v","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4526","BK4585","BK4588","MDCO","BK4139","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139657449","title":"Stock Track | BeOne Medicines Plummets 5.34% Intraday Amid Valuation Concerns Following Rebrand","url":"https://stock-news.laohu8.com/highlight/detail?id=1139657449","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139657449?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:57","pubTimestamp":1772549849,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) shares fell sharply by 5.34% during intraday trading on Tuesday, continuing a recent trend of weakness for the oncology-focused biopharmaceutical company.The decline follows the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616329697","title":"Assessing BeOne Medicines (NasdaqGS:ONC) Valuation After Its Recent Rebrand And Share Price Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2616329697","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616329697?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:23","pubTimestamp":1772547790,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) has drawn investor attention after its rebrand from BeiGene, Ltd. to BeOne Medicines AG in May 2025. The change highlights a broad oncology portfolio across commercial, clinical, and preclinical cancer therapies.\nSee our latest analysis for BeOne Medicines.\nAfter the rebrand, BeOne Medicines’ share price has been under pressure in the short term, with a 7 day share price return of a 15.18% decline and a 30 day share price return of a 7.64% decline. Its 1 year total...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/assessing-beone-medicines-nasdaqgsonc-valuation-after-its-re","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/assessing-beone-medicines-nasdaqgsonc-valuation-after-its-re","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ONC","BK4526","MDCO","BK4139","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151415813","title":"BofA International Maintains Buy Rating on BEIGENE Following Robust Product Sales Performance","url":"https://stock-news.laohu8.com/highlight/detail?id=1151415813","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151415813?lang=en_us&edition=fundamental","pubTime":"2026-03-03 15:18","pubTimestamp":1772522312,"startTime":"0","endTime":"0","summary":"BofA International released a research report highlighting BEIGENE's (06160) strong product sales in the fourth quarter of last year. Zanubrutinib sales reached $1.1 billion, representing...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK1161","06160","BK4588","BK4585","LU0588546209.SGD","LU1969619763.USD","LU1770034418.SGD","BK4139","ONC","LU1251922891.USD","LU1303224171.USD","BK1500","688235","BK1588","BK4526","LU0307460666.USD","LU1719994722.HKD","BK1583","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113559283","title":"BEIGENE Retains \"Buy\" Rating from Guojin Securities as Early-Stage Pipeline Nears Harvest","url":"https://stock-news.laohu8.com/highlight/detail?id=1113559283","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113559283?lang=en_us&edition=fundamental","pubTime":"2026-03-03 11:06","pubTimestamp":1772507214,"startTime":"0","endTime":"0","summary":"Guojin Securities has reaffirmed a \"Buy\" rating for BEIGENE (06160). The firm's core products are experiencing rapid sales growth, and its research pipeline is expected to see a series of catalysts....","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1770034418.SGD","LU1969619763.USD","BK1500","LU1719994722.HKD","BK0239","BK4139","BK1588","LU0307460666.USD","BK4588","LU0588546209.SGD","BK4585","BK1583","BK4526","LU2328871848.SGD","ONC","688235","BK1161","LU1251922891.USD","06160","LU1303224171.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614856355","title":"Beone Medicines : Leerink Partners Cuts Target Price to $364 From $370","url":"https://stock-news.laohu8.com/highlight/detail?id=2614856355","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614856355?lang=en_us&edition=fundamental","pubTime":"2026-02-27 21:13","pubTimestamp":1772198019,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZN271:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","ONC","BK4588","688235","BK4526","BK0239","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614585373","title":"Guggenheim Keeps Their Buy Rating on BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614585373","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614585373?lang=en_us&edition=fundamental","pubTime":"2026-02-27 20:38","pubTimestamp":1772195903,"startTime":"0","endTime":"0","summary":"Guggenheim analyst maintained a Buy rating on BeOne Medicines yesterday and set a price target of $410.00. The company’s shares closed yesterday at...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONC","MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614685385","title":"BeOne Medicines (ONC) Receives a Buy from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2614685385","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614685385?lang=en_us&edition=fundamental","pubTime":"2026-02-27 20:18","pubTimestamp":1772194738,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Leonid Timashev maintained a Buy rating on BeOne Medicines yesterday and set a price target of $425.00. The company’s shares cl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beone-medicines-onc-receives-a-buy-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beone-medicines-onc-receives-a-buy-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029864427.USD","LU0128525929.USD","BK4139","MDCO","LU0310800379.SGD","BK4585","LU1267930573.SGD","LU0708994859.HKD","BK4207","ONC","BK4588","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107957950","title":"BEIGENE Maintains \"Buy\" Rating from Capital Securities as First Annual Profit Achieved and Commercialization Shows Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1107957950","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107957950?lang=en_us&edition=fundamental","pubTime":"2026-02-27 14:38","pubTimestamp":1772174313,"startTime":"0","endTime":"0","summary":"Capital Securities has issued a research report maintaining a \"Buy\" rating on BEIGENE. Based on the company's latest guidance, the firm has correspondingly adjusted its profit forecasts. It is...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1303224171.USD","BK1588","LU0588546209.SGD","BK4585","BK4139","161027","LU1719994722.HKD","BK1500","06160","BK1583","LU1251922891.USD","ONC","BK0239","688235","LU0307460666.USD","LU2328871848.SGD","LU1770034418.SGD","LU1969619763.USD","BK1161","BK4588","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106587327","title":"China's AI Model Usage Surpasses US for First Time; Beigene Reports 33% Q4 Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1106587327","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106587327?lang=en_us&edition=fundamental","pubTime":"2026-02-27 07:24","pubTimestamp":1772148263,"startTime":"0","endTime":"0","summary":"China's AI model usage volume has experienced explosive growth in February, exceeding that of the United States for the first time. Data from OpenRouter, the world's largest AI model API aggregation...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014674.SGD","LU0229945570.USD","LU0359202008.SGD","688235","BK1583","LU0072462343.USD","HK0000320264.USD","89888","LU2778985437.USD","LU0762540952.USD","LU0173614495.USD","LU0320764599.SGD","LU0708995583.HKD","LU1115378108.SGD","LU1023057109.AUD","BIDU","LU0197773160.USD","BK1609","BK1095","IE0034224299.USD","HK0000306701.USD","LU0163747925.USD","LU0463099449.HKD","BK1230","BK4139","LU1328615791.USD","LU0640798160.USD","06160","LU0831093199.SGD","LU0197773673.USD","LU0149721374.USD","LU1188198961.HKD","HK0000320223.HKD","LU1251922891.USD","LU0630378429.USD","LU0856984785.SGD","LU0287142896.SGD","LU1719994722.HKD","LU1048588211.SGD","BK1575","BK1588","ONC","LU0348735423.USD","BK1161","LU0823426308.USD","LU1481107354.HKD","BK4588","LU1303224171.USD","LU0588546209.SGD","LU0456827905.SGD","09888","LU0821914370.USD","SG9999003461.SGD","LU0762542818.HKD","HK0000306685.HKD","LU0307460666.USD","BK4526","LU1969619763.USD","LU0043850808.USD","LU0164880469.USD","LU0051755006.USD","LU0164865239.USD","LU0417516738.SGD","LU0531971595.HKD","BK1587","LU2039709279.SGD","LU2476274308.USD","BK0239","SG9999002463.SGD","09678","LU0630378692.HKD","LU1831875114.USD","LU0762541174.USD","LU1770034418.SGD","SG9999002828.SGD","LU0228367735.SGD","BK4585","LU0823426480.USD","BK1615","LU0543330566.HKD","LU1048596156.SGD","LU0359201612.USD","BK1500","LU0315179316.USD","LU2328871848.SGD","LU0819121731.USD","LU0326950275.SGD","LU0871576103.HKD","LU0039217434.USD","LU0052750758.USD","LU0348825331.USD","LU0244354667.USD","LU0417516902.SGD"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":0.1222},{"period":"1month","weight":0.0463},{"period":"3month","weight":-0.0007},{"period":"6month","weight":-0.0962},{"period":"1year","weight":0.1311},{"period":"ytd","weight":0.023}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":-0.036},{"period":"3month","weight":-0.04},{"period":"6month","weight":-0.02},{"period":"1year","weight":0.1617},{"period":"ytd","weight":-0.0383}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.083709},{"month":2,"riseRate":0.6,"avgChangeRate":0.027535},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.02929},{"month":4,"riseRate":0.454545,"avgChangeRate":0.023583},{"month":5,"riseRate":0.4,"avgChangeRate":-0.019094},{"month":6,"riseRate":0.5,"avgChangeRate":0.012468},{"month":7,"riseRate":0.8,"avgChangeRate":0.147208},{"month":8,"riseRate":0.6,"avgChangeRate":0.034201},{"month":9,"riseRate":0.6,"avgChangeRate":0.069537},{"month":10,"riseRate":0.5,"avgChangeRate":-0.004517},{"month":11,"riseRate":0.6,"avgChangeRate":0.063715},{"month":12,"riseRate":0.3,"avgChangeRate":-0.043663}],"exchange":"NASDAQ","name":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","nameEN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","securityTypeName":"DR","adrRate":"1:13"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS,ONC,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票老虎,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票老虎国际,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS行情,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票行情,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股价,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股市,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票价格,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票交易,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票购买,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction